Seres Therapeutics Inc. is a biotechnology company focused on the development of novel microbiome therapeutics. By harnessing the power of the human microbiome—the trillions of microbes that inhabit the human body—the company aims to create innovative treatments for diseases associated with dysbiosis, or microbiome imbalance. Seres Therapeutics is pioneering a new class of biotherapeutics that hold potential for treating infectious, inflammatory, and metabolic diseases. The company's flagship products are developed through sophisticated genomic sequencing, data analysis, and bioinformatics, marrying cutting-edge technology with biological insights.

Operating in the dynamic biotech sector, Seres Therapeutics Inc. plays a crucial role in advancing microbiome research and translating it into practical health solutions. Their efforts contribute to the broader push within the pharmaceutical industry to develop more personalized and precision-based therapies. Based in Cambridge, Massachusetts, the company collaborates with both academic institutions and industry leaders to further their mission. Seres Therapeutics Inc.'s innovative approach positions it as a vital player in transforming how medical professionals treat complex conditions related to gut health, highlighting the industry's growth potential in microbiome-based therapies.